glp-1 receptor agonist antipsychotic weight gain study Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia Healthy weight loss maintenance with
Description
2022;20:1382-93.e19
doi: 10.1172/JCI119175
That number could climb even higher as Medicare has cleared the way for some patients to access the drugs
Consequently, ongoing research and development efforts are focused on exploring and creating novel, and more secure treatment alternatives to achieve optimal moderation of glucose levels
Not all companies are reputable, and its important to ensure that you wont simply be given medication and not followed up with by a doctor, and if possible, a registered dietitian
Other GLP-1 and glucagon co-agonists in early phase clinical trials as treatments for obesity include AZD9550 and LY3305677 (NCT05623839)
